BIO — BIO-RAD LABORATORIES, INC.

NYSE · Unknown · Unknown · CIK 12208 ·
Last close
$296.90
Market Cap
$6.44B
52W High
$312.85
52W Low
$236.73
ADV30
403,736
Next earnings
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 592,100,000 309,400,000 34,100,000 -527,100,000 9,790,000,000 507,200,000 2,938,700,000
Dec 2025 693,200,000 345,200,000 53,900,000 720,000,000 10,576,500,000 529,800,000 3,122,900,000
Sep 2025 653,000,000 343,400,000 63,900,000 -341,900,000 9,696,400,000 395,800,000 2,959,600,000
Jun 2025 651,600,000 345,300,000 77,100,000 317,800,000 10,214,100,000 369,300,000 3,085,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$510,400,000
Investing CF
$-285,800,000
Financing CF
$-229,500,000
CapEx
$-153,200,000
Dividends Paid
Buybacks
$-241,400,000
EPS Diluted TTM
$6.07
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$7,649,200,000
Inventory
$770,500,000
Receivables
$426,200,000
ST Investments
$1,057,500,000
EBIT TTM
$271,600,000
Pretax Income TTM
$222,300,000
Interest Exp TTM
$49,300,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,589,900,032
EBITDA
$444,800,000
Free Cash Flow
$229,762,496
Enterprise Value
$7,513,882,112
Total Cash
$1,564,700,032
Total Debt
$1,378,200,064
Shares Out
21,700,560
Trailing EPS
$6.01
Book Value
$255.37
ROE
2.5%
ROA
1.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,583,200,000 218,600,000 759,900,000 10,576,500,000 3,122,900,000 532,200,000
Dec 2024 2,566,500,000 269,000,000 -1,844,200,000 9,364,100,000 2,794,800,000 455,200,000
Dec 2023 2,671,200,000 337,800,000 -637,300,000 12,299,100,000 3,557,900,000 374,900,000
Dec 2022 2,802,200,000 475,100,000 -3,627,500,000 13,501,666,000 3,886,414,000 194,400,000

TTM Snapshot

Revenues TTM
$2,709,673,000
NetIncome TTM
$4,524,682,000
OpCashFlow TTM
$0
Assets (Latest)
$9,364,100,000
Forward EPS
$9.72

News headlines (Yahoo Finance, 1h cache)

Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?
2026-05-25 11:11 · Yahoo
Elliott Targets Bio-Rad After 70% Stock Collapse
2026-05-22 17:25 · Yahoo
Stocks Settle Mixed as Iran War Remains Unresolved
2026-05-18 20:35 · Yahoo
Stocks Pressured by a Rebound in Crude Prices and Bond Yields
2026-05-18 15:25 · Yahoo
Stocks Mixed as Crude Oil Prices and Bond Yields Fall
2026-05-18 14:05 · Yahoo
Sector Update: Healthcare Stocks Decline Pre-Bell Monday
2026-05-18 13:18 · Yahoo
Bio-Rad to Participate in Upcoming Investor Conferences
2026-05-08 13:00 · Yahoo
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out
2026-05-05 16:14 · Yahoo
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation,
2026-05-04 19:30 · Yahoo
How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions
2026-05-04 18:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.